Literature DB >> 27170613

Mucopolysaccharidosis type I disguised as rickets.

Partha Pratim Chakraborty1, Sugata Narayan Biswas1, Sayantan Ray2, Santosh Kumar Dey1.   

Abstract

A 16-year-old boy with widening of the large joints of the extremities and bilateral genu valgum had been extensively treated with oral vitamin D, with little clinical benefit. A diagnosis of vitamin D-resistant rickets was considered initially but a thorough clinical examination and skeletal survey was suggestive of mucopolysaccharidosis. The diagnosis was confirmed biochemically and subtype classification pointed toward the type I variety of the storage disorder. Absence of mental retardation is very unusual in mucopolysaccharidosis type I, which itself is an uncommon clinical entity. This particular disease can be misdiagnosed as vitamin D-resistant rickets in the absence of thorough systemic examination and an attentive look at the skeletal surveys. Spondyloepiphyseal dysplasia is another close differential of mucopolysaccharidosis and it should be ruled out in all cases of suspected spondyloepiphyseal dysplasia. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27170613      PMCID: PMC4885515          DOI: 10.1136/bcr-2016-215416

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Enzyme-replacement therapy in mucopolysaccharidosis I.

Authors:  E D Kakkis; J Muenzer; G E Tiller; L Waber; J Belmont; M Passage; B Izykowski; J Phillips; R Doroshow; I Walot; R Hoft; E F Neufeld
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

2.  Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.

Authors:  Jan M Wit; Lyset T M Rekers-Mombarg; Gordon B Cutler; Brenda Crowe; Tracy J Beck; Kristen Roberts; Anne Gill; Jean-Louis Chaussain; Herwig Frisch; Rafael Yturriaga; Andrea F Attanasio
Journal:  J Pediatr       Date:  2005-01       Impact factor: 4.406

3.  Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

Authors:  E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull
Journal:  Biochem Mol Med       Date:  1996-08

Review 4.  Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

Authors:  H S Scott; S Bunge; A Gal; L A Clarke; C P Morris; J J Hopwood
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

5.  Mucopolysaccharidosis I: management and treatment guidelines.

Authors:  Joseph Muenzer; James E Wraith; Lorne A Clarke
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

6.  Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

Authors:  Lorne A Clarke; J Edmond Wraith; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Marisa Sidman; Emil D Kakkis; Gerald F Cox
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

7.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

  7 in total
  2 in total

Review 1.  Misdiagnosis in mucopolysaccharidoses.

Authors:  Karolina Wiśniewska; Jakub Wolski; Lidia Gaffke; Zuzanna Cyske; Karolina Pierzynowska; Grzegorz Węgrzyn
Journal:  J Appl Genet       Date:  2022-05-13       Impact factor: 2.653

2.  Skeletal Abnormalities and VDR1 Gene Polymorphisms in Mucopolysaccharidosis Patients.

Authors:  Camelia Alkhzouz; Georgiana Cabau; Cecilia Lazea; Carmen Asavoaie; Simona Bucerzan; Andreea Manuela Mirea; Marius Farcas; Maria Miclaus Jnr; Radu Popp; Diana Miclea
Journal:  Pharmgenomics Pers Med       Date:  2021-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.